Mohammad Rubayet Hasan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Mohammad Rubayet Hasan has a total of 215 co-authors. Here are the top co-authors by number of shared publications:
- Patrick Tang
Department of Pathology and Laboratory Medicine, University of British Columbia , Vancouver, British Columbia
23 shared publications Patrick Tang
Department of Pathology Sidra Medicine Doha Qatar
19 shared publicationsSathyavathi Sundararaju
Division of Microbiology, Sidra Medicine, Doha, Qatar
14 shared publications- Laith Jamal Abu Raddad
Infectious Disease Epidemiology Group, Weill Cornell Medicine - Qatar, Cornell University, Doha, Qatar
12 shared publications - Hiam Chemaitelly
Infectious Disease Epidemiology Group, Weill Cornell Medicine - Qatar, Cornell University, Doha, Qatar
11 shared publications - Gheyath Nasrallah
Department of Biomedical Science, College of Health Sciences, QU Health, Qatar University, Doha, Qatar
10 shared publications
Latest Publications
- Open Access
- 11 November 2026
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 64 (11)
Diagnostic yield of Legionella pneumophila PCR across specimen types during a community outbreak
Legionella pneumophila is an important cause of community-acquired and healthcare-associated pneumonia. Diagnostic recommendations combine lower respiratory tract culture or molecular methods and urinary antigen testing (UAT) (1, 2). Although UAT is rapid and non-invasive, it primarily detects L. pneumophila serogroup 1 and may fail to identify infections caused by other serogroups (3–5). Molecular testing of respiratory specimens can improve case detection, but its diagnostic yield varies according to specimen type (6). Bronchoalveolar lavage (BAL) is generally considered the preferred respiratory specimen for Legionella PCR; however, bronchoscopy is an invasive procedure that may not be feasible or clinically indicated in many patients with suspected Legionella pneumonia (5, 7). Less invasive specimens, such as sputum, nasopharyngeal swabs (NPS), and urine, are easier to obtain, but data directly comparing PCR detection across different clinical specimen types remain limited, particularly during outbreak investigations (6, 8, 9).
- 11 November 2026
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 64 (11)
Open AccessDiagnostic yield of Legionella pneumophila PCR across specimen types during a community outbreak
Legionella pneumophila is an important cause of community-acquired and healthcare-associated pneumonia. Diagnostic recommendations combine lower respiratory tract culture or molecular methods and urinary antigen testing (UAT) (1, 2). Although UAT is rapid and non-invasive, it primarily detects L. pneumophila serogroup 1 and may fail to identify infections caused by other serogroups (3–5). Molecular testing of respiratory specimens can improve case detection, but its diagnostic yield varies according to specimen type (6). Bronchoalveolar lavage (BAL) is generally considered the preferred respiratory specimen for Legionella PCR; however, bronchoscopy is an invasive procedure that may not be feasible or clinically indicated in many patients with suspected Legionella pneumonia (5, 7). Less invasive specimens, such as sputum, nasopharyngeal swabs (NPS), and urine, are easier to obtain, but data directly comparing PCR detection across different clinical specimen types remain limited, particularly during outbreak investigations (6, 8, 9).
- Open Access
- 22 September 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (10)
Two Versus One COVID-19 Vaccine Dose After Prior SARS-CoV-2 Infection: A Nationwide Retrospective Cohort Study
Background: Immune protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) varies by prior infection and vaccination history. This study evaluated whether 2 coronavirus disease (COVID-19) vaccine doses after prior infection provide additional protection compared with a single dose. Methods: A national matched retrospective cohort study was conducted in Qatar from December 1, 2020-March 3, 2025. Incidence of SARS-CoV-2 reinfection and severe COVID-19 at reinfection was compared between 61 854 previously infected individuals who completed primary-series vaccination (2-dose cohort) and 61 854 matched individuals who received a single dose (single-dose cohort). Results: After 360 days of follow-up, cumulative incidence of reinfection was 5.0% (95% CI, 3.8%–6.7%) in the 2-dose cohort and 7.7% (95% CI, 6.1%–9.6%) in the single-dose cohort. No reinfections progressed to severe, critical, or fatal COVID-19 in either cohort. Relative vaccine effectiveness (rVE) of 2 doses vs 1 dose was 38.9% (95% CI, 20.4%–53.2%). The rVE was 26.9% (95% CI, −12.7%–53.4%) within <24 days, 51.8% (95% CI, 19.2%–71.2%) during Days 24–179, and 36.8% (95% CI, 0.9%–59.7%) at ≥180 days of follow-up. Subgroup analyses by time between prior infection and vaccination, prior infection variant, and vaccine type yielded broadly similar rVE estimates, while analyses stratified by age and clinical vulnerability suggested higher point estimates among older and clinically vulnerable individuals. Conclusions: Among individuals with prior infection, completion of primary-series vaccination provided modest additional protection against reinfection compared with a single dose. These findings support risk-based dose-optimization strategies in settings with constrained vaccine supply.
- 22 September 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (10)
Open AccessTwo Versus One COVID-19 Vaccine Dose After Prior SARS-CoV-2 Infection: A Nationwide Retrospective Cohort Study
Background: Immune protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) varies by prior infection and vaccination history. This study evaluated whether 2 coronavirus disease (COVID-19) vaccine doses after prior infection provide additional protection compared with a single dose. Methods: A national matched retrospective cohort study was conducted in Qatar from December 1, 2020-March 3, 2025. Incidence of SARS-CoV-2 reinfection and severe COVID-19 at reinfection was compared between 61 854 previously infected individuals who completed primary-series vaccination (2-dose cohort) and 61 854 matched individuals who received a single dose (single-dose cohort). Results: After 360 days of follow-up, cumulative incidence of reinfection was 5.0% (95% CI, 3.8%–6.7%) in the 2-dose cohort and 7.7% (95% CI, 6.1%–9.6%) in the single-dose cohort. No reinfections progressed to severe, critical, or fatal COVID-19 in either cohort. Relative vaccine effectiveness (rVE) of 2 doses vs 1 dose was 38.9% (95% CI, 20.4%–53.2%). The rVE was 26.9% (95% CI, −12.7%–53.4%) within <24 days, 51.8% (95% CI, 19.2%–71.2%) during Days 24–179, and 36.8% (95% CI, 0.9%–59.7%) at ≥180 days of follow-up. Subgroup analyses by time between prior infection and vaccination, prior infection variant, and vaccine type yielded broadly similar rVE estimates, while analyses stratified by age and clinical vulnerability suggested higher point estimates among older and clinically vulnerable individuals. Conclusions: Among individuals with prior infection, completion of primary-series vaccination provided modest additional protection against reinfection compared with a single dose. These findings support risk-based dose-optimization strategies in settings with constrained vaccine supply.
- Open Access
- 10 June 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (6) , e0351562
Microbiome analysis of bronchoalveolar lavage (BAL) specimens from immunocompromised patients with pneumonia compared to those from healthy volunteers
Background: Metagenomic sequencing of bronchoalveolar lavage (BAL) specimens is increasingly being applied for the diagnosis of lower respiratory tract infections, offering agnostic pathogen detection and a faster turnaround time. While metagenomic sequencing of BAL specimens can reveal a wide range of organisms, their clinical relevance is often unclear because of the challenge of distinguishing true pathogens from background taxa. This study compared the BAL microbiomes of immunocompromised patients with pneumonia to those of healthy volunteers, with the aim of assisting clinical interpretation of metagenomics-based approaches for diagnosing pneumonia in this patient population. Methods: BAL specimens from healthy control volunteers (n = 20) were collected during a COVID-19 vaccine trial, while residual BAL specimens from immunocompromised patients (n = 52) were obtained from the Hamilton Regional Laboratory Medicine Program (HRLMP) after standard culture and PCR testing. 16S rRNA gene amplicon sequencing was performed using Nanopore technology. Reads were classified using Minimap2 in EPI2ME, and microbiome analyses were conducted using the vegan and MaAsLin2 packages in RStudio (v2026.1.1.403). Results: Immunocompromised patients showed significantly lower bacterial read counts and reduced alpha diversity (p < 0.0001; Wilcoxon Rank-Sum test), along with higher inter-sample heterogeneity. In contrast, BAL samples from healthy controls exhibited a more homogeneous microbial profile dominated by anaerobic Gram-negative genera, including Prevotella, Veillonella, Selenomonas , and Fusobacterium . Beta diversity analyses using Bray–Curtis and Jaccard distance metrics demonstrated significant compositional separation between cohorts (PERMANOVA p = 0.001), with tight clustering of healthy controls and marked dispersion among immunocompromised samples. Differential abundance analysis identified 96 significantly altered species (q < 0.05), with immunocompromised patients showing depletion of anaerobic commensals and enrichment of clinically relevant pathogens, including Stenotrophomonas maltophilia , Enterococcus spp., Mycoplasma spp., and Nocardia spp. Conclusion: Immunocompromised patients demonstrated a markedly disrupted and heterogeneous BAL microbiome, characterized by a loss of anaerobic commensals and an enrichment of potentially pathogenic taxa. This study provides a characterization of the dysbiotic state in immunocompromised pneumonia, offering a baseline reference for future longitudinal studies and clinical trials aimed at improving the interpretation of metagenomic findings in this patient population.
- 10 June 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (6) , e0351562
Open AccessMicrobiome analysis of bronchoalveolar lavage (BAL) specimens from immunocompromised patients with pneumonia compared to those from healthy volunteers
Background: Metagenomic sequencing of bronchoalveolar lavage (BAL) specimens is increasingly being applied for the diagnosis of lower respiratory tract infections, offering agnostic pathogen detection and a faster turnaround time. While metagenomic sequencing of BAL specimens can reveal a wide range of organisms, their clinical relevance is often unclear because of the challenge of distinguishing true pathogens from background taxa. This study compared the BAL microbiomes of immunocompromised patients with pneumonia to those of healthy volunteers, with the aim of assisting clinical interpretation of metagenomics-based approaches for diagnosing pneumonia in this patient population. Methods: BAL specimens from healthy control volunteers (n = 20) were collected during a COVID-19 vaccine trial, while residual BAL specimens from immunocompromised patients (n = 52) were obtained from the Hamilton Regional Laboratory Medicine Program (HRLMP) after standard culture and PCR testing. 16S rRNA gene amplicon sequencing was performed using Nanopore technology. Reads were classified using Minimap2 in EPI2ME, and microbiome analyses were conducted using the vegan and MaAsLin2 packages in RStudio (v2026.1.1.403). Results: Immunocompromised patients showed significantly lower bacterial read counts and reduced alpha diversity (p < 0.0001; Wilcoxon Rank-Sum test), along with higher inter-sample heterogeneity. In contrast, BAL samples from healthy controls exhibited a more homogeneous microbial profile dominated by anaerobic Gram-negative genera, including Prevotella, Veillonella, Selenomonas , and Fusobacterium . Beta diversity analyses using Bray–Curtis and Jaccard distance metrics demonstrated significant compositional separation between cohorts (PERMANOVA p = 0.001), with tight clustering of healthy controls and marked dispersion among immunocompromised samples. Differential abundance analysis identified 96 significantly altered species (q < 0.05), with immunocompromised patients showing depletion of anaerobic commensals and enrichment of clinically relevant pathogens, including Stenotrophomonas maltophilia , Enterococcus spp., Mycoplasma spp., and Nocardia spp. Conclusion: Immunocompromised patients demonstrated a markedly disrupted and heterogeneous BAL microbiome, characterized by a loss of anaerobic commensals and an enrichment of potentially pathogenic taxa. This study provides a characterization of the dysbiotic state in immunocompromised pneumonia, offering a baseline reference for future longitudinal studies and clinical trials aimed at improving the interpretation of metagenomic findings in this patient population.
- Open Access
- 2 June 2026
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 14 (6) , e0076726
Evaluation of COPAN FecalSwab and eSwab collection systems for the detection of C lostridioides difficile using the BD MAX Cdiff assay
Clostridioides difficile infection (CDI) requires accurate and timely diagnostic testing to guide treatment. Nucleic acid amplification tests (NAATs) offer high sensitivity and specificity, but most assays, including the Health Canada-approved BD MAX Cdiff assay, are validated only for unpreserved stool. This presents challenges for transport, stability, and specimen sharing between tests. Swab-based collection systems such as COPAN FecalSwab and eSwab may alleviate these limitations but have not been fully evaluated on the BD MAX Cdiff assay. Residual stool specimens submitted for CDI testing were used to prepare FecalSwab and eSwab aliquots and evaluated to determine the optimal volume for BD MAX Cdiff testing. Sensitivity, specificity, and agreement were calculated using unpreserved stool as the reference method. Stability of C. difficile DNA was assessed at 4°C, room temperature, and 37°C over 14 days. Minimal variation in C. difficile PCR cycle threshold (Ct) values was observed across varying volumes of FecalSwab and eSwab media, and 100 µL was selected. C. difficile DNA was detected in all specimen types up to 14 days at different temperatures. However, a gradual increase in Ct values was noted over time for all specimens and storage temperatures, except for FecalSwab specimens stored at 4°C. FecalSwab specimens demonstrated 98.5% sensitivity and 98.4% specificity, while eSwab specimens demonstrated 97.6% sensitivity and 100% specificity against unpreserved stool. Agreement between the two swab types was 98.4%. FecalSwab and eSwab specimens prepared from unpreserved stool demonstrate excellent agreement with unpreserved stool, and provide improved options for specimen transport and stability. IMPORTANCE: This study demonstrates the utility of FecalSwab and eSwab collection media on the BD Max Cdiff assay. This addresses an important gap in the diagnosis of Clostridioides difficile infection by evaluating other specimen types beyond neat stool specimens. We demonstrate that swabs collected from stool into FecalSwab and eSwab media have excellent sensitivity and specificity compared to neat stool. Further, FecalSwab and eSwab media allow for preservation of C. difficile DNA at varying storage conditions. This could alleviate specimen transport challenges in remote or resource-limited settings.
- 2 June 2026
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 14 (6) , e0076726
Open AccessEvaluation of COPAN FecalSwab and eSwab collection systems for the detection of C lostridioides difficile using the BD MAX Cdiff assay
Clostridioides difficile infection (CDI) requires accurate and timely diagnostic testing to guide treatment. Nucleic acid amplification tests (NAATs) offer high sensitivity and specificity, but most assays, including the Health Canada-approved BD MAX Cdiff assay, are validated only for unpreserved stool. This presents challenges for transport, stability, and specimen sharing between tests. Swab-based collection systems such as COPAN FecalSwab and eSwab may alleviate these limitations but have not been fully evaluated on the BD MAX Cdiff assay. Residual stool specimens submitted for CDI testing were used to prepare FecalSwab and eSwab aliquots and evaluated to determine the optimal volume for BD MAX Cdiff testing. Sensitivity, specificity, and agreement were calculated using unpreserved stool as the reference method. Stability of C. difficile DNA was assessed at 4°C, room temperature, and 37°C over 14 days. Minimal variation in C. difficile PCR cycle threshold (Ct) values was observed across varying volumes of FecalSwab and eSwab media, and 100 µL was selected. C. difficile DNA was detected in all specimen types up to 14 days at different temperatures. However, a gradual increase in Ct values was noted over time for all specimens and storage temperatures, except for FecalSwab specimens stored at 4°C. FecalSwab specimens demonstrated 98.5% sensitivity and 98.4% specificity, while eSwab specimens demonstrated 97.6% sensitivity and 100% specificity against unpreserved stool. Agreement between the two swab types was 98.4%. FecalSwab and eSwab specimens prepared from unpreserved stool demonstrate excellent agreement with unpreserved stool, and provide improved options for specimen transport and stability. IMPORTANCE: This study demonstrates the utility of FecalSwab and eSwab collection media on the BD Max Cdiff assay. This addresses an important gap in the diagnosis of Clostridioides difficile infection by evaluating other specimen types beyond neat stool specimens. We demonstrate that swabs collected from stool into FecalSwab and eSwab media have excellent sensitivity and specificity compared to neat stool. Further, FecalSwab and eSwab media allow for preservation of C. difficile DNA at varying storage conditions. This could alleviate specimen transport challenges in remote or resource-limited settings.
- 7 May 2026
- Published by SAGE Publications in Microbial Drug Resistance
- Vol. 32 (7) , 271-279
Genome Analysis of Carbapenemase-Negative, Extensively Drug-Resistant Klebsiella pneumoniae Clinical Isolates
Extensively drug-resistant Klebsiella pneumoniae (XDR-KP) poses a major global health threat due to limited treatment options and high mortality. While the genomes of carbapenemase-positive XDR-KP strains are well-documented, there is limited data on carbapenemase-negative XDR-KP. This study characterized the genomes of two such clinical isolates, obtained from abdominal fluid and urine, that were resistant to nearly all tested antibiotics. Antimicrobial susceptibility testing was performed at the Hamilton Regional Microbiology Laboratory, ON. Carbapenemase production and the presence of carbapenemase genes were assessed using the NG-Test ® CARBA-5 and a multiplex carbapenemase PCR assay, respectively. Whole-genome sequencing via Oxford Nanopore technology revealed that both strains lacked carbapenemase genes but harbored multiple other resistance genes ( e.g., bla CTX-M-15 , qnr B1/S1, sul 1/2, dfr A17/A14, fos A) and acr R mutations. Notably, both carried omp K37 mutations, an outer membrane porin previously linked to carbapenem resistance. A number of antibiotic resistance genes were found on conjugative plasmids (IncFIB/IncFII, IncFIA, IncFIA/IncFII). Multilocus sequence typing identified different sequence types (ST307, ST45) and virulence profiling showed overlapping and distinct features, including variability in capsular and siderophore genes. These findings suggest a significant role for porin loss and efflux pump regulation in conferring resistance to broad-spectrum and last-resort antibiotics in clinical XDR-KP isolates that lack carbapenemases and other related antibiotic resistance genes.
- 7 May 2026
- Published by SAGE Publications in Microbial Drug Resistance
- Vol. 32 (7) , 271-279
Genome Analysis of Carbapenemase-Negative, Extensively Drug-Resistant Klebsiella pneumoniae Clinical Isolates
Extensively drug-resistant Klebsiella pneumoniae (XDR-KP) poses a major global health threat due to limited treatment options and high mortality. While the genomes of carbapenemase-positive XDR-KP strains are well-documented, there is limited data on carbapenemase-negative XDR-KP. This study characterized the genomes of two such clinical isolates, obtained from abdominal fluid and urine, that were resistant to nearly all tested antibiotics. Antimicrobial susceptibility testing was performed at the Hamilton Regional Microbiology Laboratory, ON. Carbapenemase production and the presence of carbapenemase genes were assessed using the NG-Test ® CARBA-5 and a multiplex carbapenemase PCR assay, respectively. Whole-genome sequencing via Oxford Nanopore technology revealed that both strains lacked carbapenemase genes but harbored multiple other resistance genes ( e.g., bla CTX-M-15 , qnr B1/S1, sul 1/2, dfr A17/A14, fos A) and acr R mutations. Notably, both carried omp K37 mutations, an outer membrane porin previously linked to carbapenem resistance. A number of antibiotic resistance genes were found on conjugative plasmids (IncFIB/IncFII, IncFIA, IncFIA/IncFII). Multilocus sequence typing identified different sequence types (ST307, ST45) and virulence profiling showed overlapping and distinct features, including variability in capsular and siderophore genes. These findings suggest a significant role for porin loss and efflux pump regulation in conferring resistance to broad-spectrum and last-resort antibiotics in clinical XDR-KP isolates that lack carbapenemases and other related antibiotic resistance genes.
- Open Access
- 29 October 2025
- Published by Elsevier in Public Health
- Vol. 249, 106016
Estimating SARS-CoV-2 infection incidence and detection rates: Demonstrating a novel surveillance method
- 29 October 2025
- Published by Elsevier in Public Health
- Vol. 249, 106016
Open AccessEstimating SARS-CoV-2 infection incidence and detection rates: Demonstrating a novel surveillance method
- Open Access
- 11 June 2025
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 63 (6) , e0140724
Treatment and diagnostic challenges associated with the novel and rapidly emerging antifungal-resistant dermatophyte, Trichophyton indotineae
Trichophyton indotineae is a recently discovered dermatophyte species that causes recalcitrant dermatophytosis. It was first reported from India and has quickly spread across the globe. The exact prevalence of T. indotineae remains unknown due to limited surveillance. It has reached epidemic proportions in the Indian subcontinent. In India, this new species has largely replaced other previously common dermatophytes. Reports from Western countries suggest most cases are imported, with some reports of local transmission. A recent report from the United Kingdom indicates that T. indotineae now accounts for 38% of dermatophyte isolates tested in their national referral laboratory. T. indotineae causes widespread, inflammatory dermatophytosis affecting large areas of the body. Dermatophytosis caused by T. indotineae is difficult to manage due to the limited availability of mycology laboratories capable of reliably identifying and performing antifungal susceptibility testing, and because of its resistance to commonly used antifungals. Culture and physiological characteristics cannot confirm identification to the species level, requiring species-level confirmation by molecular methods like internal transcribed spacer sequencing. It is important for clinicians and mycology laboratories to be aware of and consider the possibility of T. indotineae infection in patients with relevant demographic, clinical, and travel history. This would decrease delay in diagnosis, prevent inappropriate use of medications like steroids and ineffective antifungal agents, and provide opportunities to make recommendations for good hygiene practices to prevent transmission. In this mini review, we describe the emergence of T. indotineae , its diagnostic and treatment challenges, and the current state, and provide recommendations for future direction.
- 11 June 2025
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 63 (6) , e0140724
Open AccessTreatment and diagnostic challenges associated with the novel and rapidly emerging antifungal-resistant dermatophyte, Trichophyton indotineae
Trichophyton indotineae is a recently discovered dermatophyte species that causes recalcitrant dermatophytosis. It was first reported from India and has quickly spread across the globe. The exact prevalence of T. indotineae remains unknown due to limited surveillance. It has reached epidemic proportions in the Indian subcontinent. In India, this new species has largely replaced other previously common dermatophytes. Reports from Western countries suggest most cases are imported, with some reports of local transmission. A recent report from the United Kingdom indicates that T. indotineae now accounts for 38% of dermatophyte isolates tested in their national referral laboratory. T. indotineae causes widespread, inflammatory dermatophytosis affecting large areas of the body. Dermatophytosis caused by T. indotineae is difficult to manage due to the limited availability of mycology laboratories capable of reliably identifying and performing antifungal susceptibility testing, and because of its resistance to commonly used antifungals. Culture and physiological characteristics cannot confirm identification to the species level, requiring species-level confirmation by molecular methods like internal transcribed spacer sequencing. It is important for clinicians and mycology laboratories to be aware of and consider the possibility of T. indotineae infection in patients with relevant demographic, clinical, and travel history. This would decrease delay in diagnosis, prevent inappropriate use of medications like steroids and ineffective antifungal agents, and provide opportunities to make recommendations for good hygiene practices to prevent transmission. In this mini review, we describe the emergence of T. indotineae , its diagnostic and treatment challenges, and the current state, and provide recommendations for future direction.
- Open Access
- 17 February 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (3) , ofaf098
Evaluating Hospital Admission Data as Indicators of COVID-19 Severity: A National Assessment in Qatar
Background: Accurately assessing SARS-CoV-2 infection severity is essential for understanding the health impact of the infection and evaluating the effectiveness of interventions. This study investigated whether SARS-CoV-2–associated hospitalizations can reliably measure true COVID-19 severity. Methods: The diagnostic accuracy of SARS-CoV-2–associated acute care and ICU hospitalizations as indicators of infection severity was assessed in Qatar from 6 September 2021 to 13 May 2024. WHO criteria for severe, critical, and fatal COVID-19 served as the reference standard. Two indicators were assessed: (1) any SARS-CoV-2–associated hospitalization in acute care or ICU beds and (2) ICU-only hospitalizations. Results: A total of 644 176 SARS-CoV-2 infections were analyzed. The percent agreement between any SARS-CoV-2–associated hospitalization (acute care or ICU) and WHO criteria was 98.7% (95% confidence interval (CI), 98.6–98.7); however, Cohen's kappa was only 0.17 (95% CI, 0.16–0.18), indicating poor agreement. Sensitivity, specificity, PPV, and negative predictive value were 100% (95% CI, 99.6–100), 98.7% (95% CI, 98.6–98.7), 9.7% (95% CI, 9.1–10.3), and 100% (95% CI, 100–100), respectively. For SARS-CoV-2–associated ICU-only hospitalizations, the percent agreement was 99.8% (95% CI, 99.8–99.9), with a kappa of 0.47 (95% CI, 0.44–0.50), indicating fair-to-good agreement. Sensitivity, specificity, PPV, and negative predictive value were 46.6% (95% CI, 43.4–49.9), 99.9% (95% CI, 99.9–99.9), 47.9% (95% CI, 44.6–51.2), and 99.9% (95% CI, 99.9–99.9), respectively. Conclusions: Generic hospital admissions are unreliable indicators of COVID-19 severity, whereas ICU admissions are somewhat more accurate. The findings demonstrate the importance of applying specific, robust criteria—such as WHO criteria—to reduce bias in epidemiological and vaccine effectiveness studies.
- 17 February 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (3) , ofaf098
Open AccessEvaluating Hospital Admission Data as Indicators of COVID-19 Severity: A National Assessment in Qatar
Background: Accurately assessing SARS-CoV-2 infection severity is essential for understanding the health impact of the infection and evaluating the effectiveness of interventions. This study investigated whether SARS-CoV-2–associated hospitalizations can reliably measure true COVID-19 severity. Methods: The diagnostic accuracy of SARS-CoV-2–associated acute care and ICU hospitalizations as indicators of infection severity was assessed in Qatar from 6 September 2021 to 13 May 2024. WHO criteria for severe, critical, and fatal COVID-19 served as the reference standard. Two indicators were assessed: (1) any SARS-CoV-2–associated hospitalization in acute care or ICU beds and (2) ICU-only hospitalizations. Results: A total of 644 176 SARS-CoV-2 infections were analyzed. The percent agreement between any SARS-CoV-2–associated hospitalization (acute care or ICU) and WHO criteria was 98.7% (95% confidence interval (CI), 98.6–98.7); however, Cohen's kappa was only 0.17 (95% CI, 0.16–0.18), indicating poor agreement. Sensitivity, specificity, PPV, and negative predictive value were 100% (95% CI, 99.6–100), 98.7% (95% CI, 98.6–98.7), 9.7% (95% CI, 9.1–10.3), and 100% (95% CI, 100–100), respectively. For SARS-CoV-2–associated ICU-only hospitalizations, the percent agreement was 99.8% (95% CI, 99.8–99.9), with a kappa of 0.47 (95% CI, 0.44–0.50), indicating fair-to-good agreement. Sensitivity, specificity, PPV, and negative predictive value were 46.6% (95% CI, 43.4–49.9), 99.9% (95% CI, 99.9–99.9), 47.9% (95% CI, 44.6–51.2), and 99.9% (95% CI, 99.9–99.9), respectively. Conclusions: Generic hospital admissions are unreliable indicators of COVID-19 severity, whereas ICU admissions are somewhat more accurate. The findings demonstrate the importance of applying specific, robust criteria—such as WHO criteria—to reduce bias in epidemiological and vaccine effectiveness studies.
- Open Access
- 29 September 2024
- Published by Wiley in Influenza and Other Respiratory Viruses
- Vol. 18 (10) , e13357
BNT162b2 Versus mRNA‐1273 Vaccines: Comparative Analysis of Long‐Term Protection Against SARS‐CoV‐2 Infection and Severe COVID‐19 in Qatar
Background: This study provides a head‐to‐head comparison of the protection provided by the BNT162b2 and mRNA‐1273 vaccines against SARS‐CoV‐2 infection and against severe COVID‐19, covering primary series and third dose/booster vaccinations over up to 3 years of follow‐up, both before and after the emergence of the omicron variant.Methods: Two national, matched, retrospective cohort studies were conducted on Qatar's vaccinated population from December 16, 2020, to February 18, 2024. Subgroup analyses by pre‐vaccination SARS‐CoV‐2 infection history, as well as sensitivity analyses, were also conducted.Results: The adjusted hazard ratio (AHR) comparing infection incidence in those vaccinated with BNT162b2 versus mRNA‐1273 was 1.03 (95% CI: 1.02–1.05) after the primary series and 1.11 (95% CI: 1.09–1.13) after the third (booster) dose. The corresponding AHRs for any severe, critical, or fatal COVID‐19 were 1.31 (95% CI: 0.81–2.11) and 1.00 (95% CI: 0.20–4.94), respectively. Subgroup analyses by prior infection status hinted at a dose‐dependent immune imprinting effect, where a combination of two types of immunity, pre‐omicron and omicron, offered greater protection against infection than one type alone, with this effect being amplified by the higher antigen dose of mRNA‐1273 compared to BNT162b2. Sensitivity analyses confirmed the study findings.Conclusions: BNT162b2 provided slightly less protection against infection than mRNA‐1273 following both primary series and booster vaccinations while offering comparable protection against severe COVID‐19 outcomes. The findings suggested that the vaccine antigen dose in interaction with infection history may determine the extent of immune protection against infection.
- 29 September 2024
- Published by Wiley in Influenza and Other Respiratory Viruses
- Vol. 18 (10) , e13357
Open AccessBNT162b2 Versus mRNA‐1273 Vaccines: Comparative Analysis of Long‐Term Protection Against SARS‐CoV‐2 Infection and Severe COVID‐19 in Qatar
Background: This study provides a head‐to‐head comparison of the protection provided by the BNT162b2 and mRNA‐1273 vaccines against SARS‐CoV‐2 infection and against severe COVID‐19, covering primary series and third dose/booster vaccinations over up to 3 years of follow‐up, both before and after the emergence of the omicron variant.Methods: Two national, matched, retrospective cohort studies were conducted on Qatar's vaccinated population from December 16, 2020, to February 18, 2024. Subgroup analyses by pre‐vaccination SARS‐CoV‐2 infection history, as well as sensitivity analyses, were also conducted.Results: The adjusted hazard ratio (AHR) comparing infection incidence in those vaccinated with BNT162b2 versus mRNA‐1273 was 1.03 (95% CI: 1.02–1.05) after the primary series and 1.11 (95% CI: 1.09–1.13) after the third (booster) dose. The corresponding AHRs for any severe, critical, or fatal COVID‐19 were 1.31 (95% CI: 0.81–2.11) and 1.00 (95% CI: 0.20–4.94), respectively. Subgroup analyses by prior infection status hinted at a dose‐dependent immune imprinting effect, where a combination of two types of immunity, pre‐omicron and omicron, offered greater protection against infection than one type alone, with this effect being amplified by the higher antigen dose of mRNA‐1273 compared to BNT162b2. Sensitivity analyses confirmed the study findings.Conclusions: BNT162b2 provided slightly less protection against infection than mRNA‐1273 following both primary series and booster vaccinations while offering comparable protection against severe COVID‐19 outcomes. The findings suggested that the vaccine antigen dose in interaction with infection history may determine the extent of immune protection against infection.
- Open Access
- 21 November 2023
- Published by Wiley in Influenza and Other Respiratory Viruses
- Vol. 17 (11) , e13224
SARS‐CoV‐2 infection and effects of age, sex, comorbidity, and vaccination among older individuals: A national cohort study
Background: We investigated the contribution of age, coexisting medical conditions, sex, and vaccination to incidence of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection and of severe, critical, or fatal COVID‐19 in older adults since pandemic onset.Methods: A national retrospective cohort study was conducted in the population of Qatar aged ≥50 years between February 5, 2020 and June 15, 2023. Adjusted hazard ratios (AHRs) for infection and for severe coronavirus disease 2019 (COVID‐19) outcomes were estimated through Cox regression models.Results: Cumulative incidence was 25.01% (95% confidence interval [CI]: 24.86–25.15%) for infection and 1.59% (95% CI: 1.55–1.64%) for severe, critical, or fatal COVID‐19 after a follow‐up duration of 40.9 months. Risk of infection varied minimally by age and sex but increased significantly with coexisting conditions. Risk of infection was reduced with primary‐series vaccination (AHR: 0.91, 95% CI: 0.90–0.93) and further with first booster vaccination (AHR: 0.75, 95% CI: 0.74–0.77). Risk of severe, critical, or fatal COVID‐19 increased exponentially with age and linearly with coexisting conditions. AHRs for severe, critical, or fatal COVID‐19 were 0.86 (95% CI: 0.7–0.97) for one dose, 0.15 (95% CI: 0.13–0.17) for primary‐series vaccination, and 0.11 (95% CI: 0.08–0.14) for first booster vaccination. Sensitivity analysis restricted to only Qataris yielded similar results.Conclusion: Incidence of severe COVID‐19 in older adults followed a dynamic pattern shaped by infection incidence, variant severity, and population immunity. Age, sex, and coexisting conditions were strong determinants of infection severity. Vaccine protection against severe outcomes showed a dose–response relationship, highlighting the importance of booster vaccination for older adults.
- 21 November 2023
- Published by Wiley in Influenza and Other Respiratory Viruses
- Vol. 17 (11) , e13224
Open AccessSARS‐CoV‐2 infection and effects of age, sex, comorbidity, and vaccination among older individuals: A national cohort study
Background: We investigated the contribution of age, coexisting medical conditions, sex, and vaccination to incidence of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection and of severe, critical, or fatal COVID‐19 in older adults since pandemic onset.Methods: A national retrospective cohort study was conducted in the population of Qatar aged ≥50 years between February 5, 2020 and June 15, 2023. Adjusted hazard ratios (AHRs) for infection and for severe coronavirus disease 2019 (COVID‐19) outcomes were estimated through Cox regression models.Results: Cumulative incidence was 25.01% (95% confidence interval [CI]: 24.86–25.15%) for infection and 1.59% (95% CI: 1.55–1.64%) for severe, critical, or fatal COVID‐19 after a follow‐up duration of 40.9 months. Risk of infection varied minimally by age and sex but increased significantly with coexisting conditions. Risk of infection was reduced with primary‐series vaccination (AHR: 0.91, 95% CI: 0.90–0.93) and further with first booster vaccination (AHR: 0.75, 95% CI: 0.74–0.77). Risk of severe, critical, or fatal COVID‐19 increased exponentially with age and linearly with coexisting conditions. AHRs for severe, critical, or fatal COVID‐19 were 0.86 (95% CI: 0.7–0.97) for one dose, 0.15 (95% CI: 0.13–0.17) for primary‐series vaccination, and 0.11 (95% CI: 0.08–0.14) for first booster vaccination. Sensitivity analysis restricted to only Qataris yielded similar results.Conclusion: Incidence of severe COVID‐19 in older adults followed a dynamic pattern shaped by infection incidence, variant severity, and population immunity. Age, sex, and coexisting conditions were strong determinants of infection severity. Vaccine protection against severe outcomes showed a dose–response relationship, highlighting the importance of booster vaccination for older adults.